Biologics Contract Manufacturing Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Swift Approvals of Advanced Biologic Therapies
   3. Market Restraints
      1. Supply Chain Disruptions
      2. Regulatory Complexities
   4. Market Opportunities
      1. Soaring Demand for Innovative and Pliant Manufacturing Solutions to Adapt the Varied Pipeline of Biologic Therapies
   5. Market Trends
      1. Perpetual Bioprocessing Adoption
      2. Gene and Cell Therapies on the Rise
5. MARKET SEGMENTATION
   1. By Service
      1. Manufacturing
      2. Formulation and Fill-Finish
      3. Packaging and Labeling
      4. Other Services
   2. By Type
      1. Biologic Drug Substance Manufacturing
      2. Biologic Drug Product Manufacturing
   3. By Scale of Operation
      1. Commercial Operations
      2. Clinical Operations
   4. By Source
      1. Mammalian Expression Systems
      2. Non-Mammalian Expression Systems
   5. By Molecule
      1. Monoclonal Antibodies
      2. Cell Therapy & Gene Therapy
      3. Antibody-Drug Conjugates (ADCs)
      4. Vaccines
      5. Therapeutic Peptides & Proteins
      6. Other Molecule Types
   6. By Therapeutic Area
      1. Oncology
      2. Autoimmune Diseases
      3. Cardiovascular Diseases
      4. Metabolic Diseases
      5. Infectious Diseases
      6. Neurology
      7. Other Infectious Diseases
   7. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AbbVie Inc.
      2. Abzena Ltd.
      3. Boehringer Ingelheim
      4. Catalent Inc.
      5. FUJIFILM Diosynth Biotechnologies
      6. JSR Corporation
      7. Lonza Group
      8. Merck KgaA
      9. Samsung Biologics
      10. Thermo Fisher Scientific Inc.
      11. Wuxi Biologics

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global biologics contract manufacturingmarket?

The global market of biologics contract manufacturing is projected to reach USD 36.40 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global biologics contract manufacturingmarket?

The global biologics contract manufacturing market has an estimated annual growth rate of 8.3% .

Q.3. What are the recent trends of biologics contract manufacturingmarket?

Perpetual bioprocessing adoption and rise in gene and cell therapies are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in biologics contract manufacturing?

The major companies profiled in this report include AbbVie Inc., Abzena Ltd., Boehringer Ingelheim, Catalent Inc., FUJIFILM Diosynth Biotechnologies, JSR Corporation, Lonza Group, Merck KgaA, Samsung Biologics, Thermo Fisher Scientific Inc., Wuxi Biologics, among others.

Q.5. Which region is estimated to held highest CAGR inbiologics contract manufacturing market?

Asia Pacificis estimated to holdhighest CAGRin the market for biologics contract manufacturing.